Last reviewed · How we verify

Use of Mitomycin-C in trabeculectomy

Aeon Astron Europe B.V. · Phase 1 active Small molecule

Use of Mitomycin-C in trabeculectomy is a Small molecule drug developed by Aeon Astron Europe B.V.. It is currently in Phase 1 development.

At a glance

Generic nameUse of Mitomycin-C in trabeculectomy
SponsorAeon Astron Europe B.V.
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Use of Mitomycin-C in trabeculectomy

What is Use of Mitomycin-C in trabeculectomy?

Use of Mitomycin-C in trabeculectomy is a Small molecule drug developed by Aeon Astron Europe B.V..

Who makes Use of Mitomycin-C in trabeculectomy?

Use of Mitomycin-C in trabeculectomy is developed by Aeon Astron Europe B.V. (see full Aeon Astron Europe B.V. pipeline at /company/aeon-astron-europe-b-v).

What development phase is Use of Mitomycin-C in trabeculectomy in?

Use of Mitomycin-C in trabeculectomy is in Phase 1.

Related